Catalyst Wire Dossier Catalyst Wire Dossier

Dulanermin

dulanermin · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Dulanermin, covering 2011-10-07 to 2016-11-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer [Phase 1]

See pricing